Valneva Reports Record Product Sales and Major Pipeline Progress in 2019

Lyme and chikungunya passed key milestones in 2019. Significant value inflection expected in 2020 including Lyme Phase 2 data and partnering in addition to chikungunya entering Phase 3 clinical development

  • Strong financial results in 2019
  • Private traveler market sales expected to grow by up to 10% in 2020
  • Key R&D Progress reported in 2019
  • Major R&D milestones expected in 2020

Read more